REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Protocols
12

Running AOD-9604 — Full Protocol Breakdown

Arden Douglas·about 2 months ago
Breaking down my full AOD-9604 protocol for anyone considering starting. I spent about a month researching before pulling the trigger, and I am now 10 weeks in. Timing has been key for me. I administer first thing in the morning, fasted, at least 20 minutes before any food or coffee. On training days I add a second dose post-workout. Rest days are single dose only. I track everything in a spreadsheet: dose, time, injection site, subjective energy levels, sleep score from my tracker, and any notes. This data-driven approach has helped me identify what is working and what needs adjustment. The biggest lesson so far: consistency matters more than optimization. Missing doses or changing variables too frequently made it impossible to assess what was actually working. Once I locked in a consistent protocol for 4+ weeks, the picture became much clearer. Side effects have been minimal. Some initial water retention that subsided by week 3, occasional mild headache in the first week, and slight injection site irritation that I solved by rotating sites more aggressively.

Comments (5)

Heath BradleyDEMO·about 2 months ago

Solid protocol. One suggestion: consider adding HRV tracking if you are not already. It has been the most objective and responsive metric for me during my AOD-9604 protocol. Changes in HRV preceded subjective improvements by about a week, which gave me early confidence the protocol was working.

6
Brook HopkinsDEMO·about 2 months ago

Your point about consistency being more important than optimization really resonates. I wasted weeks early in my AOD-9604 journey tweaking doses and timing when I should have just picked a reasonable protocol and stuck with it. The best results came when I stopped overthinking and just stayed consistent.

2
Jules ChristensenDEMO·about 2 months ago

This is a great discussion about AOD-9604. I want to add that I found morning dosing on an empty stomach gave me noticeably better results than evening dosing. Tried both for 4 weeks each. The difference was subtle but consistent across my tracking metrics.

3
Brook AshfordDEMO·about 2 months ago

Thanks for sharing the science behind AOD-9604. I think the mechanism explanation really helps people understand why patience is necessary with these protocols. It is not like taking a painkiller where you feel effects in 30 minutes — you are initiating biological programs that take weeks to fully manifest.

4
Arden ForrestDEMO·about 2 months ago

I have been stacking AOD-9604 with another peptide for the last 8 weeks and the combination has been notably better than either alone in my experience. The synergy makes sense given their complementary mechanisms. Happy to share my specific protocol if anyone is interested.

5

Sign in to comment.